All In Biotech

NDA 210136 · Braeburn

Brixadi

Buprenorphine · Subcutaneous · Partial Opioid Agonist

Priority review

Last checked: Nov 20, 2026Latest source record: Dec 22, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2023

May 23, 2023

Approved uses

1

Original approval plus efficacy supplements

Registered trials

512

125 Phase 3, 43 recruiting

FAERS reports

26,052

19,510 serious, 5,196 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: RISK OF SERIOUS HARM OR DEATH WITH INTRAVENOUS ADMINISTRATION; BRIXADI RISK EVALUATION AND MITIGATION STRATEGY Serious harm or death could result if administered intravenously. BRIXADI forms a liquid crystalline gel upon contact with body fluids and may cause occlusion, local tissue damage, and thrombo‐embolic events, including life-threatening pulmonary emboli, if administered intravenously. (5.1) Because of the risk of serious harm or death that could result from intravenous self‐administration, BRIXADI is only available through a restricted program called the BRIXADI REMS. Healthcare settings and pharmacies that order and dispense BRIXADI must be certified in this program and comply with the REMS requirements. (5.2) WARNING: RISK OF SERIOUS HARM OR DEATH WITH INTRAVENOUS ADMINISTRATION; BRIXADI RISK EVALUATION AND MITIGATION STRATEGY See full prescribing information for...

What it is approved for

From the label in effect Dec 31, 2025.

BRIXADI is indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine. BRIXADI should be used as part of a complete treatment plan that includes counseling and psychosocial support. BRIXADI contains buprenorphine, a partial opioid agonist. BRIXADI is indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine. ( 1 ) BRIXADI should be used as part of a complete treatment plan that includes counseling and psychosocial support. ( 1 )

Mechanism: BRIXADI contains buprenorphine, a partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor.

Therapeutic areas: Pain and anesthesia

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 23, 2023 Original approval · Type 3 - New Dosage Form · priority review LetterREMSLabel
7 products under this application
  • BRIXADI · BUPRENORPHINE 96MG/0.27ML (356MG/ML) · SOLUTION, EXTENDED RELEASE, SUBCUTANEOUS · Prescription
  • BRIXADI · BUPRENORPHINE 32MG/0.64ML (50MG/ML) · SOLUTION, EXTENDED RELEASE, SUBCUTANEOUS · Prescription
  • BRIXADI · BUPRENORPHINE 16MG/0.32ML (50MG/ML) · SOLUTION, EXTENDED RELEASE, SUBCUTANEOUS · Prescription
  • BRIXADI · BUPRENORPHINE 128MG/0.36ML (356MG/ML) · SOLUTION, EXTENDED RELEASE, SUBCUTANEOUS · Prescription
  • BRIXADI · BUPRENORPHINE 64MG/0.18ML (356MG/ML) · SOLUTION, EXTENDED RELEASE, SUBCUTANEOUS · Prescription
  • BRIXADI · BUPRENORPHINE 24MG/0.48ML (50MG/ML) · SOLUTION, EXTENDED RELEASE, SUBCUTANEOUS · Prescription
  • BRIXADI · BUPRENORPHINE 8MG/0.16ML (50MG/ML) · SOLUTION, EXTENDED RELEASE, SUBCUTANEOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Buprenorphine" as an intervention, any sponsor and status, largest first.

All 512 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug dependence4,161
  • overdose2,163
  • drug abuse2,123
  • pain2,065
  • drug ineffective1,702
  • death1,624
  • toxicity to various agents1,608
  • drug withdrawal syndrome1,547
  • nausea1,336
  • emotional distress1,253
  • off label use1,108
  • vomiting1,099

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20043
200534
20063
20071
20083
200930
201083
2011231
2012384
2013322
2014355
2015572
2016572
2017790
20181,367
20192,127
20202,121
20213,316
20223,529
20232,088
20243,019
20253,182
20261,920

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Brixadi (Buprenorphine)

2024 spending

$11.2M

Beneficiaries

1,795

7,546 claims

Per beneficiary

$6,242

$5,048.33 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$362,555
2024$11,205,219

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,775 on PubMed

Sponsor: Braeburn

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.